A pharmaceutically acceptable salt of thiadiazol-piperidine substituted compound for plasmodium related diseases

PK144812BActive Publication Date: 2026-10-21NOVARTIS AG
0 Cites 0 Cited by

Patent Information

Application Number
PK202300066
Authority / Receiving Office
PK · PK
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-01-30
Publication Date
2026-10-21
Patent Text Reader

Abstract

The present invention provides a pharmaceutically acceptable salt of a compound of formula (Ic); wherein: Z is N; Y1 is C(OH)CH2NH2; R1 is C1-4alkyl; R2a is C14alkyl; R2b is hydrogen and R3b, R3c, R3d, and R3e is each independently selected from hydrogen, C1-4alkyl, amino, -X1 -R3a, NH-X1-R3a, hydroxy-substituted-C1-4alkyl, C1-4alkoxy-substitutedC1-4alkyl, hydroxy, oxo, halo, -X1 -CO2H, -X1 -CO2NH2, -X1 -SO2C14alkyl, -X1 -SO2N(C1-4alkyl)2, and -X1 -C3-6-cycloalkyl. It relates to the salt considered to be useful to treat or prevent plasmodium related diseases, for example malaria.
Need to check novelty before this filing date? Find Prior Art